SOURCE: Innoviva, Inc.

Innoviva, Inc.

January 27, 2016 16:05 ET

Innoviva to Report Fourth Quarter and Full Year 2015 Financial Results on February 3, 2016

SOUTH SAN FRANCISCO, CA--(Marketwired - Jan 27, 2016) - Innoviva, Inc. (NASDAQ: INVA) announced today that it will report financial results for the fourth quarter and full year ended December 31, 2015 after market close on Wednesday, February 3, 2016. Innoviva management will host a webcast and conference call at 5:00 p.m. EST that day to discuss the financial results and provide a corporate update.

To participate in the live call by telephone, please dial (877) 837-3908 from the U.S., or (973) 890-8166 for international callers. A live webcast of the call will be available online from the investor relations section of the company website at www.inva.com and will be archived there for 30 days. A telephone replay of the call will be available by dialing (855) 859-2056 from the U.S., or (404) 537-3406 for international callers and entering the confirmation code 36373209.

About Innoviva
Innoviva, formerly known as Theravance, Inc., is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Innoviva and GSK. Under the agreement with GSK, Innoviva is eligible to receive associated royalty revenues from RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and, if approved and commercialized, VI monotherapy, as well. In addition, Innoviva retains a 15 percent economic interest in future payments made by GSK for earlier-stage programs partnered with Theravance BioPharma, Inc. For more information, please visit Innoviva's website at www.inva.com.

ANORO®, RELVAR®, BREO® and ELLIPTA® are trademarks of the GlaxoSmithKline group of companies.

(INVA-F)

Contact Information